Standard

The immunopathology of sepsis and potential therapeutic targets. / van der Poll, Tom; van de Veerdonk, Frank L.; Scicluna, Brendon P. et al.

In: Nature reviews. Immunology, Vol. 17, No. 7, 2017, p. 407-420.

Research output: Contribution to journalReview articleAcademicpeer-review

Harvard

van der Poll, T, van de Veerdonk, FL, Scicluna, BP & Netea, MG 2017, 'The immunopathology of sepsis and potential therapeutic targets', Nature reviews. Immunology, vol. 17, no. 7, pp. 407-420. https://doi.org/10.1038/nri.2017.36

APA

van der Poll, T., van de Veerdonk, F. L., Scicluna, B. P., & Netea, M. G. (2017). The immunopathology of sepsis and potential therapeutic targets. Nature reviews. Immunology, 17(7), 407-420. https://doi.org/10.1038/nri.2017.36

Vancouver

van der Poll T, van de Veerdonk FL, Scicluna BP, Netea MG. The immunopathology of sepsis and potential therapeutic targets. Nature reviews. Immunology. 2017;17(7):407-420. Epub 2017. doi: 10.1038/nri.2017.36

Author

van der Poll, Tom ; van de Veerdonk, Frank L. ; Scicluna, Brendon P. et al. / The immunopathology of sepsis and potential therapeutic targets. In: Nature reviews. Immunology. 2017 ; Vol. 17, No. 7. pp. 407-420.

BibTeX

@article{f4c646f489bd4b8680655620881af19c,
title = "The immunopathology of sepsis and potential therapeutic targets",
abstract = "Sepsis is defined as a life-threatening organ dysfunction that is caused by a dysregulated host response to infection. In sepsis, the immune response that is initiated by an invading pathogen fails to return to homeostasis, thus culminating in a pathological syndrome that is characterized by sustained excessive inflammation and immune suppression. Our understanding of the key mechanisms involved in the pathogenesis of sepsis has increased tremendously, yet this still needs to be translated into novel targeted therapeutic strategies. Pivotal for the clinical development of new sepsis therapies is the selection of patients on the basis of biomarkers and/or functional defects that provide specific insights into the expression or activity of the therapeutic target",
author = "{van der Poll}, Tom and {van de Veerdonk}, {Frank L.} and Scicluna, {Brendon P.} and Netea, {Mihai G.}",
year = "2017",
doi = "10.1038/nri.2017.36",
language = "English",
volume = "17",
pages = "407--420",
journal = "Nature reviews. Immunology",
issn = "1474-1733",
publisher = "Nature Publishing Group",
number = "7",

}

RIS

TY - JOUR

T1 - The immunopathology of sepsis and potential therapeutic targets

AU - van der Poll, Tom

AU - van de Veerdonk, Frank L.

AU - Scicluna, Brendon P.

AU - Netea, Mihai G.

PY - 2017

Y1 - 2017

N2 - Sepsis is defined as a life-threatening organ dysfunction that is caused by a dysregulated host response to infection. In sepsis, the immune response that is initiated by an invading pathogen fails to return to homeostasis, thus culminating in a pathological syndrome that is characterized by sustained excessive inflammation and immune suppression. Our understanding of the key mechanisms involved in the pathogenesis of sepsis has increased tremendously, yet this still needs to be translated into novel targeted therapeutic strategies. Pivotal for the clinical development of new sepsis therapies is the selection of patients on the basis of biomarkers and/or functional defects that provide specific insights into the expression or activity of the therapeutic target

AB - Sepsis is defined as a life-threatening organ dysfunction that is caused by a dysregulated host response to infection. In sepsis, the immune response that is initiated by an invading pathogen fails to return to homeostasis, thus culminating in a pathological syndrome that is characterized by sustained excessive inflammation and immune suppression. Our understanding of the key mechanisms involved in the pathogenesis of sepsis has increased tremendously, yet this still needs to be translated into novel targeted therapeutic strategies. Pivotal for the clinical development of new sepsis therapies is the selection of patients on the basis of biomarkers and/or functional defects that provide specific insights into the expression or activity of the therapeutic target

U2 - 10.1038/nri.2017.36

DO - 10.1038/nri.2017.36

M3 - Review article

C2 - 28436424

VL - 17

SP - 407

EP - 420

JO - Nature reviews. Immunology

JF - Nature reviews. Immunology

SN - 1474-1733

IS - 7

ER -

ID: 3779017